The GIP component appears to blunt GLP-1-associated nausea, which is one reason discontinuation rates for tirzepatide are lower than for pure GLP-1 agonists at equivalent weight-loss doses [1]
The subcutaneous injections available in the United States are dulaglutide (Trulicity, Eli Lilly, for type 2 diabetes), liraglutide (Victoza, Novo Nordisk, for type 2 diabetes), semaglutide (Ozempic, Novo Nordisk, for type 2 diabetes and Wegovy, for weight loss), tirzepatide (Mounjaro, Eli Lilly, for type 2 diabetes), and Zepbound (Eli Lilly, for weight loss)
Calcif Tissue Int
Gadella (Addgene plasmid no
Important Regulatory & Legal Notice Research & Development Use Only: This product is supplied strictly for laboratory research, analytical testing, and scientific evaluation